User:Ahayes87/sandbox

Noasis Scientific Holdings, Inc. (known as "Noasis Bio-Pharmaceuticals") is focused on the mergers/acquisitions of pharmaceutical, bio-technology and healthcare companies as well as the discovery, development, manufacuring and distribution of branded and generic therapeutic drugs to combat illness and disease and improve the lives and outcomes of patients in the following areas: Cardiovascular, Neurological, Infectious Disease and Oncological. We understand that these areas of medicine are some of the most hard fought research projects scientists ever take on.

Founded in 2008, the company's controlling founder, Andrew J. Hayes serves as Chairman of the Board & Chief Executive Officer. The company focuses on being a highly integrated and diversified bio-pharmaceutical company. There integration model involves more than just pharmaceuticals but also the businesses that allow for the creation of pharmaceutical development.

History
Noasis Scientific Holdings, Inc. was founded in 2008 by Scientist and pharmaceutical entreprenuer Andrew J. Hayes and incorporated on June 3rd 2016 under the Laws of the State of Wyoming.

Noasis is a bio-technology and pharmaceutical healthcare company Headquartered out of Dubuque, Iowa with satelite offices in New York City, NY and San Diego, CA. Seven years of researching the past; to the discovery of molecular models and drug development potential at the present; we are building the future for a better tomorrow by acquiring, developing and manufacturing some of the most complex solutions to combat the  illnesses that have not yet addressed the evolving needs of patients worldwide

Noasis Pharmaceutical's is pushing the boundaries of Biological, Chemical, and Bio-defense systems to create a truly integrative company that successfully creates unlimited possiblities. Today, the work and scientific research being done at Noasis Pharmaceuticals and its subsidiaries are forever changing the way we heal, the way we fight, and the way we construct our interactions

Corporate Affairs
Noasis Pharmaceuticals Worldwide Holdings has two distinct classes of Common Stock: Its Class A Common Stock has authorized Issuance of 250 million shares and for every 1 share of Class A stock owned is entitled to 1 vote on business matters (including election of the Board of Directors); Its Class B Common Stock has authorized Issuance of 125 million shares and for every 1 share of Class B stock owned is entitled to 1/50th vote on business matters. The company also has authorized Issuance of 125 million shares of Convertible Preferred Stock with no voting rights but has preferential treatment in terms of dividend payments and liquidation.

Noasis Scientific Holdings CEO is Andrew J. Hayes. Each year Andrew writes an Annual Shareholder Letter giving his opinions on the forecasting year's Bio-pharmaceutical and bio-technology future.

As of December 31st 2018, Andrew J. Hayes & his family owns approximately million shares of Class A common stock and 26,000,000 shares of Class B Common Stock.

Corporate Governance
The current members of the Board of Directors of Noasis Scientific Holdings, Inc. are Andrew J. Hayes B.S., Rochelle L. McCann, Kayci L. Schumacher, Rose Cashman, Carson P. Stanley M.B.A., Dr. Warren Gall M.D., Dr. Adib Kassas M.D., Richard Birkenbeuel, Alexander Persaud, Dr. James Hamblin M.D., Dr. Karen Glover Ph.D., David Koch Ph.D., Dante M. Price M.B.A., Zach Wiltshire M.S.,

Oil & Natural Gas
Many have wondered why a Pharmaceutical company would own Oil and Natural Gas companies. The truth is oil and natural gas are a key component in the manufacturing of pharmaceutical products, Engineering, Bio-technology, and Healthcare products, and as part of the companies ongoing pursuit to become a highly integrated bio-pharmaceutical company.

Engineering
Seattle Genetics is a wholly owned subsidiary of Noasis Pharmaceuticals Worldwide.

Bio-Technology
Texnacon Industries is a wholly owned subsidiary of Noasis Pharmaceuticals Worldwide. Texnacon Industries is focused on Human Biological Nanotechnology and Bio-Defense Systems. Its current projects include AHRIAS, NGABPS, and GEMOCI.

AHRIAS - Acquire Health Resources Interactive Application's System. Noasis's Patented bio-tech/

Pharmaceuticals/Biologics
Branded and Generic Drug Discovery and Manufacturing is the Core business of Noasis Pharmaceuticals Worldwide Holdings. Noasis not only researches, develops and manufactures several products in its pipeline, the company also focuses on the acquisition of pharmaceutical drugs from other companies.

Healthcare
Noasis Pharmaceuticals owns and operates hospitals, assisted-living facilities, and medical supply companies.